BioMarin Pharma (BMRN) Misses Q4 EPS by 7c
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $56.60 +1.25%
EPS Growth %: -34.0%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
MAYS, CRMT, REPL, More
EPS Growth %: -34.0%
Financial Fact:
Weighted average common shares outstanding, basic: 167.71M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q4 EPS of ($0.30), $0.07 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $358.3 million versus the consensus estimate of $351.62 million.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion, versus the consensus of $1.48 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
- Goldman "broadly" raises estimates for LTL and truckload stocks
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
